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Abstract  
Misuse of prescribed and over the counter (OTC) codeine containing medicines is an 
increasing public health concern in recent times. Studies have called for low threshold 
treatment services for individuals experiencing codeine dependence using buprenorphine 
naloxone therapy.  We present a scoping review of clinical case presentation literature on the 
use of buprenorphine-naloxone in the treatment of codeine dependence. Seven records (four 
single case studies and three case series) on codeine dependence treated with buprenorphine-
naloxone were included. Five themes emerged following a review of the cases for the 
treatment of codeine dependence with buprenorphine-naloxone. They are: (1) Patient 
Profiles; (2) History of Codeine Misuse; (3) Medical Problems; (4) Use of Other Substances; 
and (5) Buprenorphine-naloxone in the treatment of Codeine Dependence. The review 
highlights the complexities of patients with regards to pain, psychiatric illness, poly substance 
use and iatrogenic dependence, with findings encouraging in terms of patient stabilisation and 
recovery. 
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Introduction 
Misuse of prescribed and over the counter (OTC) codeine containing medicines is an 
increasing public health concern in recent times. Misuse definitions vary, but are broadly 
defined as ‘the use of a medicine, with or without a doctor’s prescription, clearly outside of 
accepted medical practice or guidelines, for recreational purposes or in the framework of 
self-medication, in greater dosages or for longer periods than were prescribed, in which the 
risks and problems associated with use outweigh the benefits’ (Casati, Sedefov, and Pfeiffer-
Gerschel 2012:229-230). Codeine or 3-methylmorphine is a methylated morphine derivative 
present in the poppy seed, and is a short acting, weak to mid-range opiate (Tremlett, 
Anderson, and Wolf 2010) used for the symptomatic relief of mild to moderate pain or cough 
(Derry, Karlin, and Moore 2013). OTC formulations contain varying strengths of codeine in 
different countries (Van Hout and Norman 2015). Misuse of codeine combination analgesic 
products (ibuprofen or acetaminophen) is increasing where available OTC (McAvoy, Dobbin, 
and Tobin 2011). Stronger regulatory responses to tackle misuse have been debated (Tobin, 
Dobbin, and McAvoy 2013).  
 
Typical side effects on use include altered perceptions and emotional responses to pain, 
euphoria and sedation, and the development of tolerance within relatively short timeframes 
on repeated use (Sproule, Busto, Somer, Romach, and Sellers 1999; Frei, Nielsen, Dobbin, 
and Tobin 2010; Kelly and Madadi 2012; Babalonis, Lofwall, Nuzzo, Siegel, and Walsh, 
2013). Increased use of codeine stimulates neuro-adaptation and dependence (Nielsen, 
Cameron, and Pahoki 2010; McAvoy et al. 2011), with withdrawal symptomatology 
including preoccupation with seeking and taking codeine, craving and lack of control over 
use (Romach, Sprouole, Sellers, Somer, and Busto 1999). The variability of genetic 
metabolic response contributes to risk of misuse (Sproule et al. 1999; Ingelman-Sundberg, 
Sim, Gomez, and Rodriguez-Antona 2007; Frei et al. 2010; Nielsen et al. 2010). Increases in 
mortality are reported (Pilgrim, Dobbin, and Drummer 2013; Handley and Flanagan 2014), 
with particular adverse health consequences such as hypokalaemia, gastrointestinal 
haemorrhage, acute haemorrhagic necrotizing pancreatitis and inflammatory bowel 
conditions centring on the misuse of combination analgesics containing codeine (Lambert 
and Close 2005; Dutch 2008; Evans, Chalmers-Watson, and Gearry 2010; Ernest, Chia, and 
Corallo 2010; Frei et al. 2010; Ng et al. 2011; Van Hout, Bergin, Foley, Rich, Rapca, Harris, 
et al. 2014). Psychiatric co-morbidity such as anxiety, depression and dysphoria is also 
reported (Romach et al. 1999; Dobbin and Tobin 2008; Frei et al. 2010; Nielsen et al. 2010; 
McAvoy et al. 2011; Manchia, Alda, and Calkin, 2013). 
 
Treatment uptake for OTC codeine dependence is increasing in Australia, South Africa and 
the UK (Myers, Siegfried, and Parry 2003; McDonough 2011; Stannard 2013; Nielsen, 
Roxburgh, Bruno, Lintzeris, Jefferson, and Degenhardt 2015a). Recent qualitative studies 
have explored patient experiences of misuse and dependence in Ireland, the UK, South Africa 
and Australia (Nielsen et al. 2010; Nielson, Cameron, and Lee 2011; Nielsen, Cameron, and 
Pahoki 2013; Cooper 2011, 2013; Van Hout 2015; Van Hout, Horan, Santlal, Rich, and 
Bergin 2015a; Van Hout, Rich, Dada, and Bergin 2015b). Recent studies have called for 
enhanced targeted design of appropriate treatment services for individuals experiencing 
codeine dependence (Nielsen, Bruno, Murnion, Dunlop, Degenhardt, et al. 2015b; Marr and 
Hill 2015) as these individuals are different to other opioid dependent patients (Nielsen et al. 
2011; Nielsen, Murnion, Dunlop, Degenhardt, Demirkol, et al. 2015c), by virtue of their lack 
of recognition of problematic use, perceptions around drug addiction and lack of self-
identification, and experiences of stigma relating to mainstream drug addiction services  
(Nielsen et al. 2010; Reed, Bond, Witton, Cornish, Hickman, and Strang 2011; Van Hout et 
al. 2015a;b Kean 2015).   
 
Despite these differences, there is a limited evidence base to underpin best practice guidelines 
for the treatment of this form of opioid dependence (Cooper 2013; Conroy and Hill 2014; 
Hard 2014), with approaches generally centring on substitution treatment (National Institute 
for Health and Clinical Excellence 2007).  One such form of pharmacological treatment of 
opioid dependence is buprenorphine –naloxone, commonly used in low threshold treatment 
of heroin dependence, and which is an effective opioid agonist treatment for prescription and 
OTC opioid analgesic dependence (Sigmon, Dunn, Badger, Heil, and Higgins 2009; Weiss, 
Potter, Fiellin, Byrne, Connery, et al. 2011). It is reported to benefit patients with codeine 
dependence (Department of Health -England and the Developed Administrations 2007; 
Stannard 2013; Royal College of General Practitioners 2014a-d; Nielsen et al. 2015; Van 
Hout et al. 2015a;b). There is an increasing evidence base of case studies implicating use of 
this therapeutic agent in successful treatment outcomes (Hard 2014; Conroy and Hill 2014; 
Kean 2015; Marr and Hill 2015; Van Hout, Delargy, Ryan, Flanagan, and Gallagher 
2015c).Decisions to treat using buprenorphine naloxone centre on its safety profile (ceiling 
effect on respiratory depression and lower abuse potential), in comparison to other common 
opioid agonist treatments (ie methadone), reduced symptoms of withdrawal on cessation of 
use, lack of association with QT prolongation, and most importantly for these patients is the 
ability to continue with employment and enhanced social functioning, attributed to clarity of 
thought and the dislike of the sedating effect of methadone (Conroy and Hill 2014; New 
Zealand Ministry of Health 2014; Fiellin et al. 2014; Hard 2014). Additionally, with 
buprenorphine- naloxone patient transfer into opioid agonist treatment is easier, with 
stabilisation achieved relatively easily, and with cessation relatively easily within short 
timeframes.  In contrast, safe titration of methadone dose takes longer, and with high dose 
methadone posing an overdose risk. With this in mind, we therefore present a scoping review 
of available case presentation literature on the use of buprenorphine-naloxone in the 
treatment of codeine dependence.  
 
Methods 
Scoping review methods are emerging as an increasingly popular and accepted approach 
across many different disciplines in recent times (Anderson, Allen, Peckham, and Goodwin 
2008; Arksey and O'Malley 2005; Daudt, van Mossel, and Scott 2013; Levac, Colquhoun, 
and O'Brien 2010; Pham, Rajić, Greig, Sargeant, Papadopoulos, et al. 2014). A scoping 
review is generally used to determine the significance of a full systematic review, summarise 
and disseminate findings of the research, and identify gaps in the current literature (Arksey 
and O'Malley 2005; Levac, Colquhoun, and O'Brien 2010). 
 
For the purpose of this study, Daudt et al.’s (2013:8) scoping review definition was 
employed. They define a scoping review as a form of research synthesis with objectives to 
“map the literature on a particular topic or research area and provide an opportunity to 
identify key concepts; gaps in the research; and types and sources of evidence to inform 
practice, policymaking, and research”. The decision to undertake a scoping review was due 
to this type of review being advantageous when the topic has not previously been reviewed at 
length (Hidalgo Landa, Szabo, Le Brun, Owen, and Fletcher 2011). Furthermore, scoping 
reviews are utilised as standalone projects that provide widespread descriptive summaries of 
the literature, comprising of a broad range of study designs and methodologies (Arksey and 
O’Malley 2005; Brien, Lorenzetti, Lewis, Kennedy, and Ghali 2010). Scoping reviews use 
meticulous and transparent methods to recognise and analyse literature relevant to a specific 
topic (Arksey and O'Malley 2005; Rumrill, Fitzgerald, and Merchant 2010).  
 
The present study adhered to a six stage method as developed by Arskey and O’Malley 
(2005) with advanced recommendations by Levac et al. (2010). These stages included: (1) 
identifying the central research question, (2) searching for relevant studies, (3) selection of 
studies, (4) charting the data, (5) and collating, summarizing and reporting the results.  The 
scoping study began with the formation of the research team including those with expertise in 
the areas of pharmacy, addiction, harm reduction; and scoping and systematic reviews (Levac 
et al. 2010). The research team identified the underpinning research question: “what do we 
know about cases of treatment of codeine dependence using buprenorphine-naloxone?” The 
review aimed to collect extant clinical case presentation literature on codeine dependence 
treatment using buprenorphine-naloxone.   
 
A comprehensive list of search terms was devised by the team which combined the terms 
‘Codeine’ with ‘Buprenorphine- naloxone’; ‘Suboxone ®’; and ‘clinical case presentation’. 
To ensure all literature relevant to the present study were included; a comprehensive search 
was carried out using the following databases: Science Direct, EBSCO Host, PsychINFO, 
and PubMED. The initial search identified 5,535 articles, and following exclusion of animal 
studies, duplicates, and lack of relevance specifically to the treatment of codeine with 
buprenorphine-naloxone, six case studies/series papers were identified to directly relate to the 
case presentations describing treatment of codeine dependence with buprenorphine-naloxone. 
We additionally scrutinised the bibliographies of studies identified in the literature search. 
This process discovered one further reference (n=1) with no subsequent records identified 
(Arskey and O’Malley 2005). A total of seven case presentation records (four single case 
studies and three case series) on codeine dependence treated with buprenorphine-naloxone 
were included in the review. See Figure 1.  
 
Insert Figure 1 about here 
 
Results 
Case studies were conducted in Scotland (Conroy and Hill 2014; Marr and Hill 2015), Wales 
(Hard 2014), United Kingdom (Kean 2015), Australia (Nielsen et al. 2015d,e) and Ireland 
(Van Hout et al. 2015). Details relating to the single case studies (Conroy and Hill 2014; 
Marr and Hill 2015; Hard 2014; Kean 2015) and the case series (Nielsen et al. 2015d,e; Van 
Hout et al. 2015c) are presented in Table 1. Five themes emerged following a review of the 
cases for the treatment of codeine dependence with buprenorphine-naloxone, as follows (1) 
Patient Profiles; (2) History of Codeine Misuse; (3) Medical Problems; (4) Use of Other 
Substances; and (5) Buprenorphine-naloxone in the treatment of Codeine Dependence. 
 
Insert Table 1 about here 
 
Patient Profiles 
Of the four single case studies, three patients were female with their ages ranging from early 
to mid-twenties (Conroy and Hill 2014; Hard 2014; Marr and Hill 2015), with one male in his 
mid-thirties (Kean 2015).  The three case series consisted of 53 female and 23 male 
participants with an age range of 38 to 57 years (Nielsen et al. 2015d,e; Van Hout et al. 
2015c).  
History of Codeine Misuse 
Reasons for initiation to codeine use were: post-surgery pain (Conroy and Hill 2014); 
myalgic encephalopathy (Hard 2014); back pain (Kean 2015); dental pain (Marr and Hill 
2015; Van Hout et al. 2015c); pain relief not specified (n=47); previous opioid dependence 
(n=8) (Nielsen et al. 2015d,e); pain relief for a broken wrist; migraines (Van Hout et al. 
2015c), and reason not stated (n=14) (Nielsen et al. 2015d). Length of codeine use varied 
starting at two years (Marr and Hill, 2014), then 3 years (Van Hout et al. 2015c), 4 years 
(Kean 2015; Nielsen et al. 2015d), 7 years (Nielsen et al. 2015e), 10 years (Conroy and Hill 
2014; Hard 2014; Van Hout et al. 2015c) and one case noted length of use as “several years” 
and another as “a long history” (Van Hout et al. 2015c).  
Types of codeine medicines used both alone and/or combined were: codeine (Kean 2015); 
co-codamol, a combination analgesic containing codeine with paracetamol,  (Marr and Hill 
2014; Kean 2015; Van Hout et al. 2015c); dihydrocodeine (Conroy and Hill 2014; Van Hout 
et al. 2015c); codeine-ibuprofen (Van Hout et al. 2015c); and codeine-paracetamol (Hard 
2014). Two studies (Nielsen et al. 2015d,e) did not specify the type of codeine medication 
used.  Great variation in daily doses of codeine was evident beginning at 30mg (Hard 
2014)180mg (Conroy and Hill 2014); 240mg (Kean 2015); 360mg (Conroy and Hill 2014); 
1205mg (Kean 2015); and the highest dose was 2940mg daily (Hard 2014). One study 
(Nielsen et al. 2015c) did not state dosage and another (Nielsen et al. 2015e) stated a mean 
daily dosage of 564mg.  All studies reported misuse of prescribed codeine medications 
however two reported the use of diverted codeine medicines (Conroy and Hill 2014; Kean 
2015), one via street dealers (Conroy and Hill 2014) the other did not report where the 
diverted medicines were obtained (Kean 2015). 
 
Medical Problems  
Medical complications arising from excessive and long term use of codeine containing 
products included: Addisons Disease; haematemesis; pancreatitis; and gastro-intestinal (GI) 
haemorrhage (Van Hout et al. 2015c); collapse (Conroy and Hill 2014); constipation (Marr 
and Hill 2014); withdrawal symptoms related to codeine dependence (Conroy and Hill 2014; 
Hard 2014; Kean 2015). One study reported a series of mental health disorders: anxiety 
disorder (n=14); bipolar disorder (n=7); eating disorders (n=2); depression (n=31); 
psychiatric comorbidity (n=42); post-traumatic stress disorder (PTSD) (n=5); and 
schizophrenia (n=3) (Nielsen et al. 2015d). 
Use of Other Substances 
Other substances used concurrently with codeine by some of the patients were: nicotine 
(n=24); stimulants (n=3); cannabis (n=5); problematic alcohol (n=14); and benzodiazepines 
(n=17) (Nielsen et al. 2015d). Van Hout et al. (2015) reported the use of hypnotics; tramadol; 
and cough medicines with codeine containing medications. Heroin use was reported as a 
replacement for di-hydrocodeine by one patient when a prescription for di-hydrocodeine was 
unavailable to her (Conroy and Hill 2014) and 7 other patients reported a previous history of 
heroin use (Nielsen et al. 2015d).  Three studies did not state any substances being used 
concurrently with codeine (Hard 2014; Kean 2015; Marr and Hill, 2014).  
Buprenorphine-naloxone in the treatment of Codeine Dependence  
Treatments other than and prior to treatment using buprenorphine-naloxone were methadone 
maintenance treatment (Conroy and Hill 2014; Nielsen et al. 2015d) and previous episodes of 
treatment for addiction (Nielsen et al. 2015d), however this was not reported in all studies.  
Length of treatment using buprenorphine-naloxone varied and was reported as: one month 
(Nielsen et al. 2015e); three months (Van Hout et al. 2015c) several months (Conroy and Hill 
2014), six months (Hard 2014; Kean 2015); and 11 months (Van Hout et al. 2015c) in 
duration, but was not reported in some cases (Marr and Hill, 2014; Nielsen et al. 2015d). 
Doses ranged between 4mg and 24mg daily with tapering of doses reported: 24mg to 16mg 
(Conroy and Hill 2014); 16mg to 10mg (Hard 2014); 8mg to 0mg (Kean, 2014) and 16mg 
tapering 2mg each month, stable on 8mg at time of study (Marr and Hill, 2014). Van Hout et 
al. (2015) reported dosages of between 4mg and 14mg per day. Median doses of 12mg to 
16mg was reported by Nielsen et al. (2015b). One study did not report dosage levels (Nielsen 
et al. 2015d). One patient was reported as abstinent at the time of the case study (Kean 2015) 
and some patients were stabilised at the time of writing the paper (Conroy and Hill 2014; 
Hard 2014; Marr and Hill, 2014; Van Hout et al. 2015c) however this factor was not reported 
on all cases (Nielsen et al. 2015d,e).  
Psychosocial treatments reported were: treatment for anxiety, peer mentoring, 12 step 
fellowship (Hard 2014); Social Behaviour and network Therapy (Kean 2015); CBT (Hard 
2014; Kean 2015); and counselling (Van Hout et al. 2015c). One study reported psychosocial 
treatment was part of the process but no detail was given on which type of treatment (Conroy 
and Hill 2014). 
Discussion 
We present here a review of available case literature on the use of buprenorphine-naloxone in 
the treatment of codeine dependence. The seven case presentation (single and series) papers 
highlight the growing number of presentations where codeine is the primary drug of misuse 
and dependence. The wide range of people who become dependent on OTC codeine 
combination analgesics range from those with a history of complex and multiple addictions, 
personality and psychological difficulties to those where initial consumption of codeine 
occurred to treat legitimate pathology (Van Hout et al. 2015). The issue of iatrogenic opioid 
analgesic dependence confounds treatment pathways and recovery outcomes (Stannard 2013; 
Marr and Hill 2015).Therefore, distinguishing between iatrogenic opioid dependence and that 
of misuse and problematic use leading to dependence is essential in facilitating enhanced 
treatment, particularly for pain patients (Marr and Hill 2015). The need for prescriber and 
pharmacist assessment of risk for codeine dependence through initial and ongoing routine 
screening is argued for (Bergin, Norman, Foley, Harris, Rapca, et al. 2015; Hard 2014; Van 
Hout et al. 2015; 2014). Of note was the high dose consumption of these codeine containing 
products, where recommended adult daily oral doses of codeine range between 30-60mg 
every four hours and to a maximum of 240mg  (Derry et al. 2013).  
 
Codeine dependent user demographics are different when compared to other strong 
prescription opioid dependent users, and pointing to the widening of patient access to 
buprenorphine naloxone as a low threshold treatment option (Nielsen et al. 2011; 2015c). 
Buprenorphine-naloxone treatment is more common for codeine dependent users than 
methadone, as it favours those who socially function well and wish to remain at work, 
thereby, reducing the potential for stigma and restrictive aspects often associated with 
methadone (Nielsen et al. 2014; Van Hout et al. 2015). The potential of effective opioid 
assisted treatment using buprenorphine naloxone with psychosocial interventions/counselling 
to treat this form of opioid dependence is gaining support from both clinicians (Conroy and 
Hill 2014; Hard 2014; Kean 2015) and codeine dependent users themselves (Van Hout et al. 
2015a,b). The codeine dependent cases reviewed here highlights a more favourable response 
to treatment consisting of the use of buprenorphine-naloxone within a biopsychosocial 
approach, thereby creating for more positive recovery outcomes for individuals underpinned 
by enhanced social and occupational functioning.  
In terms of dose titrations, codeine is of lower potency than many other opioids with codeine 
dependent individuals using lower doses of opioids when compared to oral morphine 
equivalents (Nielsen et al. 2015c). The Australian case series demonstrated that codeine 
dependent users were receiving higher sublingual buprenorphine doses than when calculated 
against the dose of codeine consumed and were similar to that of other service users being 
treated for heroin dependence or more potent opioids (Nielsen et al. 2015b). This suggests 
that clinicians using standard opioid conversion calculations (Fine, Portenoy, et al. 2009) are 
at risk of underestimating the buprenorphine-naloxone dose that codeine dependent users 
actually require resulting in poorer clinical outcomes, and also, suggesting that high doses of 
buprenorphine-naloxone (up to 32mg daily) appears safe and well tolerated by this group of 
codeine dependent users (Nielsen et al. 2015b).  While individual dose titration is best 
practice (Gowing, Ali, Dunlop, Farrell, and Lintzeris 2014) a recommendation that codeine 
dependent individuals receive similar doses to that of other opioid dependents is suggested 
(Nielsen, Hillhouse, Mooney, Fahey, and Ling 2012), thereby improving treatment retention 
(Fareed, Vayalapalli, Casarella, and Drexler 2012).  
Conclusion 
A scoping review presented the clinical case presentation (single and series) literature in 
relation to the use of buprenorphine-naloxone in the treatment of codeine dependence. 
Findings illustrate the complexities of these distinct opiate dependent patients with regards to 
pain, psychiatric illness, poly substance use and iatrogenic dependence. Given this distinct 
form of opioid dependence, buprenorphine-naloxone as treatment modality is encouraging in 
terms of patient stabilisation and recovery, and warrants expansion of access within low 
threshold treatment service design. Further research is warranted to explore how the various 
treatment approaches (buprenorphine-naloxone and psychosocial interventions) influence 
long term outcomes for this unique cohort of codeine dependent individuals. 
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Figure 1. Flowchart  
 
5,535 articles identified through 
database searching (3 duplicates 
removed) 
5,523 records excluded for lack of 
relevance specificically to the treatment of 
codeine with Buprenorphine, and animal 
studies.
Final number of articles charted  
n = 7
3 duplicates 
removed
1 added  as a result of 
scrutinising bibliographies  
of studies identified 
9 articles screened for 
inclusion criteria
Figure
Table 1 Clinical Case Presentations for Codeine Dependence treated with Buprenorphine-naloxone  
Authors & Title Year Country 
No. of 
Cases 
Profile(s) Codeine use Medical 
Complications/Other 
Substance use 
Other 
Treatment 
Buprenorphine 
Treatment 
Psychosocial 
treatment 
Conroy and Hill. 
 
Failure to identify or 
effectively manage 
prescription opioid 
dependence acted as a 
gateway to heroin use—
buprenorphine/naloxone 
treatment and recovery in a 
surgical patient. 
2014 Scotland 1 Female, Early 
20’s. 
Reason for 
codeine use: 
Prescribed DHC 
for pain relief 
following 
laparoscopy in 
2004. 
Length of 
codeine use: 10 
years 
DHC Began at 
180mg daily. 
Over 4 years 
continued this 
and additional 
non-prescribed 
DHC bought 
from street 
dealers bringing 
daily dose to 
360mg. 
Medical Complications: A 
sudden collapse led to her GP 
being informed of her opioid 
use. 
Her prescription was not 
authorized and she 
experienced withdrawal 
symptoms. 
Other Substances: 
Went on to consume 3 bags of 
heroin daily, and then back to 
consuming just diverted DHC 
until 2009. 
 
MMT for 21 
months. 
 
After relapse in 
2013 with DHC 
daily, for several 
months 
buprenorphine 
was started. 
24mg tapered to 
16mg daily at 
time of writing 
paper. 
 
 
Yes but no details 
given. 
Hard 
 
Management of opioid 
painkiller dependence in 
primary care: ongoing 
recovery with 
buprenorphine/naloxone. 
 
2014 Wales 1 Female, Mid 
20’s. 
Reason for 
codeine use: 
Myalgic 
encephalopathy 
(generalised 
aches and pains) 
in 2002. 
Length of 
codeine use: 
10 years 
 
Codeine-
paracetamol 
30mg/500mg 
q.i.d. 
This dose 
doubled over 4 
years (16 tabs 
per day). 
After 10 years 
her dose had 
risen to 2940mg 
daily (85 tabs 
daily). 
Medical Complications: 
Withdrawal symptoms 6-8 
hours of not taking codeine-
paracetamol. 
Other Substances: 
 
 Buprenorphine 
16mg for 
6months. 
Tapered to 
10mg daily at 
time of writing 
paper. 
A keyworker for 
anxiety; CBT; peer 
mentoring; and also 
12 step fellowship. 
Kean 
 
Illicit and over-the-counter 
codeine dependence after 
acute back pain-successful 
treatment and ongoing 
2015 UK 1 Male, Mid 30’s. 
Reason for 
codeine use: 
Low back pain 
initially in 2010. 
Length of 
Prescribed 
240mg of 
codeine daily, 
leading to 
1250mg daily 
through use of 
Medical Complications: 
Withdrawal symptoms when 
trying to reduce codeine use 
Other Substances: 
 
 Began on 8mg 
and tapered off 
completely in 6 
months. Opioid 
abstinent in May 
2015. 
Social Behaviour and 
Network Therapy; 
CBT 
Table
recovery after 
buprenorphine/naloxone 
taper 
codeine use: 
4 years. 
diverted codeine 
and OTC co-
codamol. 
Marr and Hill 
 
Optimising service 
provision for prescribed 
opioid analgesic 
dependence. 
2015 Scotland 1 Female, 24 years 
old. 
Reason for 
codeine use: 
Dental Pain 
initially. 
Length of 
codeine use: 
2 years. 
 
Prescribed Co-
Codamol 
30/500mg (daily 
dose not noted). 
OTC Co-
Codamol /500mg 
then added. 
Prescribed 
tramadol 50mg 
(1-2 when 
required) given. 
 
Medical Complications: 
Episode of severe constipation 
led to GP awareness of 
codeine abuse. 
Other Substances: 
 
 16/4mg tapering 
off by 2mg 
every 2 months 
No 
Nielsen et al. 
 
Comparing treatment‐
seeking codeine users and 
strong opioid users: 
Findings from a novel case 
series. 
2015 Australia 53 Females (n=35). 
Males (n=18). 
Mean age = 38.6 
Reason for 
codeine use: 
Pain (n=35) 
Previous opioid 
dependence 
(n=4) 
Other/not stated 
(n=14) 
Length of 
codeine use: 
Median=4.75yrs 
 
Not stated Medical Complications: 
Psychiatric comorbidity (n=42) 
Anxiety disorder (n=14) 
Depression (n=31) 
Schizophrenia (n=3) 
Bipolar disorder (n=7) 
PTSD (n=5) 
Eating disorder (n=2) 
Other Substances (Current): 
Nicotine (n=24) 
Cannabis (n=5) 
Stimulants (n=3) 
Problematic alcohol (n=14) 
Benzo’s (n=17) 
IDU (n=0) 
Other Substances (History): 
Heroin (n=7) 
 
 
Previous 
Alcohol/Drug 
Treatment 
(n=27). 
Methadone 
(n=3) 
Bup 
maintenance 
(n=24). 
Bup Reduction 
(n=21). 
Not stated 
Nielsen et al. 
 
Treating codeine 
dependence with 
buprenorphine: Dose 
2014 Australia 19 Female (n=16) 
mean age 41.2.  
Male (n=3) 
Reason for 
codeine use: 
Mean dose 
codeine (specific 
type not stated) = 
564mg 
Medical Complications: 
 
Other Substances: 
Not stated Median dose = 
12mg (day 7). 
16mg (day 28). 
All (n=19) in 
BMT for 
Not stated 
requirements and induction 
outcomes from a 
retrospective case series in 
New South Wales, 
Australia. 
Initially for pain 
= 63%. 
Previous heroin 
use (n=4). 
 
Length of 
codeine use: 
mean = 7.7 years 
 
Nicotine = 42% 
Problematic alcohol = 32% 
Problematic Benzo = 42% 
 
1month 
Van Hout et al. 
 
Dependence on over the 
counter (otc) codeine 
containing analgesics: 
Treatment and recovery 
with buprenorphine 
naloxone. 
2015 Ireland 4 Female (n=2) 
Male (n=2) 
Ages 44-57yrs 
Reasons for 
codeine use: 
Pain due to 
broken wrist; 
dental pain; 
migraines; and 
back pain. 
Length of 
codeine use: 
3 years, 10 
years, “several 
years” and one 
stated “a long 
history”. 
Codeine 
containing 
tablets: OTC 
Codeine-
Ibuprofen; Co-
codamol; and 
DHC.  
Between 12-72 
tabs per day 
Medical Complications: 
Haematemesis; Pancreatitis; 
Addisons Disease; GI 
haemorrhage  
Other Substances: 
Alcohol; hypnotics; and cough 
medicines 
 Between 4mg 
and 14mg per 
day 
Counselling 
 
 
 
